Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Neuroimmune activation as a novel therapeutic approach for IBD

Cel

NeurIMM has been designed to investigate the commercial and technical viability of a novel, targeted therapy for Inflammatory Bowel Disease (IBD), based on a recently uncovered signaling axis between intestinal type 3 innate lymphoid cells (ILC3s) and enteric glial cells. This discovery by the team of Prof. Henrique Veiga-Fernandes in the ERC CoG grant 647274 ‘GliaInnateSensing’ was recently published in Nature (Ibiza et al, Nature 2016). NeurIMM proposes the use of a glial cell-derived immunomodulator to restore intestinal homeostasis, by inducing a tissue protective immune response. Importantly, this novel therapy will also promote tissue healing to reverse immune-cell mediated tissue damage, leading to improved outcomes for the patient. This could have major implications for patients suffering from IBD. In addition, this approach also has potential as an effective therapy against cancer, (pediatric) gastroenteritis, and other inflammatory disorders.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

ERC-POC - Proof of Concept Grant

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) ERC-2017-PoC

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Instytucja przyjmująca

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD
Wkład UE netto
€ 150 000,00
Koszt całkowity
€ 150 000,00

Beneficjenci (1)